Literature DB >> 25557653

Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.

Shanel B Bhagwandin1, Samer Naffouje, George Salti.   

Abstract

INTRODUCTION: Peritoneal surface malignancy is increasingly treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). This is associated with potentially high morbidity. We analyzed the incidence of delayed major complications following CRS plus HIPEC.
METHODS: Delayed events were chosen as those which occurred after discharge from the hospital following CRS plus HIPEC and prior to 90 days. Major complications included any adverse event requiring intervention or intensive care unit admission.
RESULTS: One hundred thirty six patients underwent 140 procedures. Eight patients (5.7%) developed delayed major complications. Complications were pancreatic pseudocyst/pancreatitis (n = 3), abdominal wall dehiscence (n = 2), gastric perforation (n = 1), and ureteral stricture with associated hydronephrosis (n = 2). All of the patients had undergone multivisceral resections. Seven patients achieved complete cytoreduction (cc ≤ 1). Mean peritoneal carcinomatosis index (PCI) was 15.25 ± 5.33 (6-22). Standard of care was met for the management of all the complications and all patients recovered following intervention without any further morbidity or mortality.
CONCLUSION: There is a lack of report of the delayed major complications in patients undergoing CRS plus HIPEC in the literature. Awareness should be raised among health care providers regarding possible occurrence of such late complications given that many patients undergo CRS plus HIPEC remotely from their localities.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRS plus HIPEC; delayed complications; intervention; major; readmission

Mesh:

Substances:

Year:  2014        PMID: 25557653     DOI: 10.1002/jso.23834

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  [Hyperthermic intraperitoneal chemotherapy].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

2.  Association of intraoperative gross hematuria with acute kidney injury after cytoreductive surgery.

Authors:  Yumi Mitani; Yohei Arai; Yoshimasa Gohda; Hideaki Yano; Isao Kondo; Emi Sakamoto; Daisuke Katagiri; Fumihiko Hinoshita
Journal:  Pleura Peritoneum       Date:  2022-02-18

3.  Routine prophylactic ureteral stenting before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Safety and usefulness from a single-center experience.

Authors:  Paola Fugazzola; Federico Coccolini; Matteo Tomasoni; Enrico Cicuttin; Maria Grazia Sibilla; Francesca Gubbiotti; Andrea Lippi; Mario Improta; Giulia Montori; Marco Ceresoli; Michele Pisano; Luca Ansaloni
Journal:  Turk J Urol       Date:  2019-09-01

4.  Gastric perforation following cytoreductive surgery and perioperative intraperitoneal chemotherapy: a case series of six.

Authors:  Lee S Kyang; Nayef A Alzahrani; Jing Zhao; David L Morris
Journal:  World J Surg Oncol       Date:  2017-02-10       Impact factor: 2.754

5.  Postoperative intraperitoneal hyperthermic perfusion improve survival for advanced gastric cancer.

Authors:  Hong-Wei Zhang; Jian-Jun Yang; Ji-Yang Zheng; Li Sun; Xue-Wen Yang; Guo-Cai Li
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Risk factors for gastric perforation after cytoreductive surgery in patients with peritoneal carcinomatosis: Splenectomy and increased body mass index.

Authors:  Martina Aida Angeles; Carlos Martínez-Gómez; Mathilde Del; Federico Migliorelli; Manon Daix; Anaïs Provendier; Muriel Picard; Jean Ruiz; Elodie Chantalat; Hélène Leray; Alejandra Martinez; Laurence Gladieff; Gwénaël Ferron
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.